Barely Significant
← all excerpts

The journey of remdesivir: from Ebola to COVID-19.

Drugs Context · 2020 · PMC7250494 · PMID 32547625

Europe PMCDOI
1
hedged sentence
0.0590
closest p · 1.2× alpha
0.0590
boldest claim

The sentences

showed a trendp =0.059so close (0.05 < p ≤ 0.1)
The results also showed a trend toward survival benefit with remdesivir (mortality of 8% in remdesivir arm versus 11.6% in placebo, p =0.059).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.